Related Experiment Video
Updated: Mar 23, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
Premixed insulin regimens in type 2 diabetes: pros
Maria Ida Maiorino1, Giuseppe Bellastella2, Katherine Esposito2
1Diabetes Unit, Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy.
Endocrine
|March 23, 2016
Summary
Premixed insulin offers a convenient option for type 2 diabetes management, achieving similar glycemic control to basal bolus regimens. Patient-centered choices are key for effective insulin intensification.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Rising type 2 diabetes prevalence necessitates intensified treatment for hyperglycemia.
- Premixed insulin formulations offer convenience with combined rapid- and intermediate-acting components.
- Basal bolus insulin is often considered the standard for glycemic control.
Purpose of the Study:
- To compare the efficacy of intensified insulin regimens in type 2 diabetes.
- To evaluate premixed insulin regimens against basal bolus and basal plus regimens.
- To inform patient-centered decisions regarding insulin therapy intensification.
Main Methods:
- Comparative analysis of intensified insulin regimens (basal bolus, premixed, basal plus).
- Assessment of HbA1c reduction, hypoglycemic events, and weight gain.
- Evaluation of treatment outcomes at a similar injection frequency (2 shots/day).
Main Results:
- Intensified insulin regimens, including premixed and basal bolus, achieve similar HbA1c reduction, hypoglycemia, and weight gain.
- Premixed insulin demonstrated a significant 0.2% HbA1c decrease compared to basal plus at 2 shots/day.
- Individual patient preferences and resources are crucial for treatment adaptation.
Conclusions:
- Premixed insulin is a viable option for intensifying type 2 diabetes treatment, offering comparable outcomes to basal bolus regimens.
- Treatment decisions should prioritize patient needs, safety, and minimizing burden.
- Safe insulin initiation and intensification are paramount, focusing on reducing hypoglycemia and weight gain.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
01:27Insulin Formulations: Types and Delivery
1.1K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
1.1K
01:06Oral Hypoglycemic Agents: Glinides
926
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
926
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.9K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.9K
01:22Diabetes Mellitus: Type 2 and Gestational
5.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K
01:22Diabetes Mellitus: Overview and Type I Subtype
5.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.9K